Live
Endpoints NewsOptum Rx unveils pharmacy model with clear fees, building on transparency pushClinical OMICsFactors Predicting Poor Outcomes in Hypertrophic Cardiomyopathy UncoveredClinical OMICsSlow-Growing Breast Cancer Cells May Explain Why Relapse Happens Decades LaterClinical OMICsAsthma Drug Formoterol Shows Potential to Reverse MASHEndpoints NewsRezdiffra is exceeding Wall Street's expectations as the MASH market takes shapeBioWorldAppointments and advancements for May 11, 2026BioWorldFinancings for May 11, 2026BioWorldIn the clinic for May 11, 2026BioWorldOther news to note for May 11, 2026BioWorldRegulatory actions for May 11, 2026BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drugEndpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
BioPharma Dive Mar 27, 2026

Novartis targets Xolair successor in buyout of startup Excellergy

Novartis targets Xolair successor in buyout of startup Excellergy

Original
Body unavailable. Use the original source.